Related Experiment Video
Updated: May 9, 2026
Generation and Expansion of Primary, Malignant Pleural Mesothelioma Tumor Lines
Published on: April 21, 2022
Does the expression of BCL2 have prognostic significance in malignant peritoneal mesothelioma?
Krishna Pillai1, Mohammad H Pourgholami, Terence C Chua
1Department of Surgery, St. George Hospital, University of New South Wales Kogarah, NSW 2217, Australia.
Unlabelled:
Background Malignant peritoneal mesothelioma (MPM) is a rare neoplasm of the peritoneal membrane that is causally related to asbestos exposure. Survival after treatment is poor. Current therapy involving hyperthermic intraperitoneal chemotherapy has improved survival in selective patients. In the past, several prognostic factors have been identified in MPM patients and this has prompted the development of new therapies and patient management. Since BCL2, an antiapoptotic oncoprotein, is a favourable prognostic factor in breast cancer, we investigated to determine the significance of BCL2 in MPM. Materials and Methods Forty two archival patient tumour sections embedded in paraffin blocks were sectioned and subjected to immunohistochemistry to detect BCL2. The staining intensity and abundance was classified using standard procedures and classified into two groups (0-4 = low & 5-8 = high expression). The distribution of BCL2 groups was examined in the different clinicopathological categories to determine prognosis using Kaplan-Meier survival analysis.
Results:
Univariate analysis revealed that in almost all clinicopathological categories, high BCL2 expression predisposed patients to a favourable prognosis. Independent of BCL2 expression, univariate analysis also showed that male gender, sarcomatoid histology, high PCI and age at diagnosis ≥ 60 years were associated poor prognosis. Multivariate analysis indicated that for all tumours, males and females, high BCL2 expression was associated with good prognosis. Further, independent of BCL2, age ≥ 60 years is an unfavourable prognostic factor.
Conclusion:
Expression of BCL2 may serve to distinguish prognosis within the individual clinicopathological categories. BCL2 is also an independent variable in all tumours, males and females, with high expression being associated with good prognosis.
Insights
High BCL2 expression is a favorable prognostic indicator for malignant peritoneal mesothelioma (MPM) patients. This finding holds true across various clinicopathological categories and independently for all MPM tumors in males and females.
Area of Science:
- Oncology
- Cancer Research
- Molecular Pathology
Background:
- Malignant peritoneal mesothelioma (MPM) is a rare cancer linked to asbestos exposure with poor survival rates.
- Current treatments like hyperthermic intraperitoneal chemotherapy offer survival benefits in select MPM patients.
- Identifying prognostic factors is crucial for developing new therapies and improving patient management in MPM.
Purpose of the Study:
- To investigate the prognostic significance of BCL2, an antiapoptotic oncoprotein, in malignant peritoneal mesothelioma (MPM).
- To determine if BCL2 expression levels correlate with patient survival outcomes in MPM.
Main Methods:
- Immunohistochemistry was performed on 42 archival MPM tumor sections to detect BCL2 expression.
- BCL2 staining intensity and abundance were quantified and categorized into low (0-4) and high (5-8) expression groups.
- Kaplan-Meier survival analysis was used to examine the association between BCL2 expression groups and clinicopathological factors.
Main Results:
- Univariate analysis indicated that high BCL2 expression was associated with a favorable prognosis in most clinicopathological categories of MPM.
- Multivariate analysis confirmed that high BCL2 expression is an independent predictor of good prognosis in all MPM tumors, irrespective of gender.
- Age at diagnosis ≥ 60 years and sarcomatoid histology were identified as independent unfavorable prognostic factors.
Conclusions:
- BCL2 expression can help differentiate prognosis within specific clinicopathological categories of malignant peritoneal mesothelioma.
- High BCL2 expression is an independent favorable prognostic factor for MPM patients, including males and females.
- Further research into BCL2's role may lead to improved therapeutic strategies for MPM.
